(Q35989499)

11 August 2017

1 reference

title

Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis (English)

1 reference

11 August 2017

0 references

1 reference

Roberts L

1

1 reference

PubMed ID

15610214

11 August 2017

McColl GJ

series ordinal

2

1 reference

PubMed ID

15610214

11 August 2017

language of work or name

1 reference

1 December 2004

1 reference

Internal Medicine Journal

11 August 2017

1 reference

11 August 2017

34

1 reference

11 August 2017

687-693

1 reference

11 August 2017

12

1 reference

Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Decline after immobilisation and recovery after remobilisation of synovial fluid IL1, TIMP, and chondroitin sulphate levels in young beagle dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00710.X

10.1111/J.1445-5994.2004.00710.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15610214